# US 2010/0143304 A1 · Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143304 A1
- Document ID: US20100143304A1
- Status: Published application
- Kind: A1
- Application number: 12/520,500
- Filed: 2008-01-30
- Published: 2010-06-10
- Earliest claimed: 2007-01-30
- Assignees: Cedars-Sinai Medical Center
- Inventors: Pedro R. Lowenstein; Maria Castro
- Web page: https://patentgrep.com/patent/US20100143304A1

## CPC

- C12N 15/86: Viral vectors
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/1211: {Thymidine kinase (2.7.1.21)}
- C07K 2319/00: Fusion polypeptide
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2830/00: Vector systems having a special element relevant for transcription
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods useful in transgene expression are provided. Herpes simplex virus type 1 thymidine kinase sequences (“TK sequences”) are used to enhance transgene expression in first generation and high capacity adenoviral vectors. An mCMV promoter-driven β-galactosidase-expressing cassette is combined with TK sequences through direct fusion of the cDNA's. β-galactosidase (transgene) expression is enhanced independent of adenoviral vector selection. Methods of enhancing transgene expression employing the inventive adenoviral vectors are provided, along with pharmaceutical preparations comprising the inventive vectors and kits for enhanced transgene expression.

## Claims

### Claim 1

An expression vector capable of enhancing the expression of a transgene, comprising:
a polynucleotide encoding herpes simplex type 1 thymidine kinase; and the transgene.

### Claim 2 (depends on 1)

The expression vector of claim 1, wherein the expression vector is selected from the group consisting of a recombinant vector, an adenoviral vector and a high capacity adenoviral vector.

### Claim 3 (depends on 1)

The expression vector of claim 1, further comprising an mCMV promoter.

### Claim 4 (depends on 3)

The expression vector of claim 3, wherein the mCMV promoter is operably linked to the transgene and the polynucleotide encoding herpes simplex type 1 thymidine kinase.

### Claim 5 (depends on 1)

The expression vector of claim 1, wherein the polynucleotide encoding herpes simplex type 1 thymidine kinase is fused to the transgene.

### Claim 6

A method of enhancing the expression of a transgene, comprising:
providing an expression vector comprising:
a polynucleotide encoding herpes simplex type 1 thymidine kinase; and
the transgene;
introducing the expression vector into a cell; and
maintaining the cell under conditions permitting increased expression of the transgene.

### Claim 7 (depends on 6)

The method of enhancing the expression of a transgene of claim 6, wherein the cell is maintained in vivo.

### Claim 8 (depends on 6)

The method of enhancing the expression of a transgene of claim 6, wherein the cell is maintained in vitro.

### Claim 9 (depends on 6)

The method of enhancing the expression of a transgene of claim 6, wherein the expression vector is selected from the group consisting of a recombinant vector, an adenoviral vector and a high capacity adenoviral vector.

### Claim 10 (depends on 6)

The method of enhancing the expression of a transgene of claim 6, wherein the expression vector further comprises an mCMV promoter.

### Claim 11 (depends on 10)

The method of enhancing the expression of a transgene of claim 10, wherein the mCMV promoter is operably linked to the polynucleotide encoding herpes simplex type 1 thymidine kinase and the transgene.

### Claim 12 (depends on 6)

The method of enhancing the expression of a transgene of claim 6, wherein the polynucleotide encoding herpes simplex type 1 thymidine kinase is fused to the transgene.

### Claim 13

A pharmaceutical preparation, comprising:
an expression vector capable of enhancing the expression of a transgene, comprising:
a polynucleotide encoding herpes simplex type 1 thymidine kinase; and
the transgene; and
a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The pharmaceutical preparation of claim 13, wherein the expression vector is selected from the group consisting of a recombinant vector, an adenoviral vector and a high capacity adenoviral vector.

### Claim 15 (depends on 13)

The pharmaceutical preparation of claim 13, wherein the expression vector further comprises an mCMV promoter.

### Claim 16 (depends on 15)

The pharmaceutical preparation of claim 15, wherein the mCMV promoter is operably linked to the polynucleotide encoding herpes simplex type 1 thymidine kinase and the transgene.

### Claim 17 (depends on 13)

The pharmaceutical preparation of claim 13, wherein the polynucleotide encoding herpes simplex type 1 thymidine kinase is fused to the transgene.

### Claim 18

A kit for enhanced expression of a transgene, comprising:
an expression vector, comprising:
a polynucleotide encoding herpes simplex type 1 thymidine kinase; and
the transgene;
a pharmaceutically acceptable carrier; and
instructions for use.

### Claim 19 (depends on 18)

The kit for enhanced expression of a transgene of claim 18, wherein the expression vector is selected from the group consisting of a recombinant vector, an adenoviral vector and a high capacity adenoviral vector.

### Claim 20 (depends on 18)

The kit for enhanced expression of a transgene of claim 18, wherein the expression vector further comprises an mCMV promoter.

### Claim 21 (depends on 20)

The kit for enhanced expression of a transgene of claim 20, wherein the mCMV promoter is operably linked to the polynucleotide encoding herpes simplex type 1 thymidine kinase and the transgene.

### Claim 22 (depends on 18)

The kit for enhanced expression of a transgene of claim 18, wherein the polynucleotide encoding herpes simplex type 1 thymidine kinase is fused to the transgene.

### Claim 23 (depends on 18)

The kit for enhanced expression of a transgene of claim 18, wherein the kit is configured for in vivo expression of the transgene.

### Claim 24 (depends on 18)

The kit for enhanced expression of a transgene of claim 18, wherein the kit is configured for in vitro expression of the transgene.
